A Phase III, Multi-Center, Randomized, Open-Label, Active-Controlled Trial to Compare the Efficacy and Safety of F-627 and GRAN in the Prophylactic Treatment for Chemotherapy-Induced Neutropenia
Latest Information Update: 25 Apr 2025
At a glance
- Drugs Efbemalenograstim alfa (Primary) ; Filgrastim
- Indications Chemotherapy-induced damage; Neutropenia
- Focus Registrational; Therapeutic Use
- Sponsors Evive Biotech; Generon (Shanghai) Corporation
Most Recent Events
- 13 Sep 2024 Results assessing the efficacy and safety of F-627, also known as efbemalenograstim alfa (Ryzneuta R) in reducing neutropenia compared with filgrastim (GRAN R) were published in the BMC Cancer.
- 27 Nov 2019 New trial record